The main role of the PDCO is to prospectively guide sponsors or companies on how to consider a medicine’s use in children during its development. In this context, the committee assesses the content of paediatric investigation plans as well as applications for a full or partial waiver and for deferrals.

The PDCO will elect a new vice-chair at its meeting in September 2025.